-+ 0.00%
-+ 0.00%
-+ 0.00%

INmune Bio adds Sanofi rare-disease executive Duane Clark, dealmaker James Sapirstein to board

PUBT·09/14/2026 11:04:34
Listen to the news
INmune Bio adds Sanofi rare-disease executive Duane Clark, dealmaker James Sapirstein to board
  • INmune Bio added R. Duane Clark II, Sanofi’s General Manager, U.S. Rare Diseases, to its board as it prepares Ebstrocel commercialization.
  • Clark has 40+ years in pharma, including rare-disease launches, market access, M&A integration, sales and marketing leadership.
  • James Sapirstein joined the board, bringing 40+ years in biopharma business development, licensing, commercialization, financing, and public-company leadership.
  • Sapirstein held senior roles at Gilead, Bristol Myers Squibb, Roche, Eli Lilly, Serono; founded Tobira, acquired by Allergan for up to USD 1.7 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140700PRIMZONEFULLFEED9825786) on September 14, 2026, and is solely responsible for the information contained therein.